NanoViricides (NNVC)
Develops host-mimetic antiviral candidates for multiple viral diseases.
$1.57
vs last close+0.04 (+2.61%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 9.35% | 2.37M shares | |
|---|---|---|---|
| 51 holders · as of Jun 30, 2026 | |||
| Other | 90.65% | 23.03M shares | |
| remainder | |||
25.40M company shares as of Sep 13, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (21.65M in the company's Sep 23, 2026 report, 25.40M elsewhere); stakes use the report.
13F, as of Jun 30, 2026
51 holders · 2.37M shares · 10 new positions · 20 increased · 5 reduced · 9 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 919.3K | 3.62% | +407.8K | Aug 13, 2026 |
| Geode Capital Management, LLC | 216.0K | 0.85% | −9.4K | Aug 12, 2026 |
| Connective Capital Management, LLC | 185.2K | 0.73% | +185.2Knew | Aug 13, 2026 |
| BlackRock, Inc. | 158.8K | 0.63% | +1 | Aug 7, 2026 |
| Vanguard Fiduciary Trust Co | 131.9K | 0.52% | +41.9K | Aug 13, 2026 |
| Renaissance Technologies LLC | 128.6K | 0.51% | −6.3K | Aug 13, 2026 |
| Miller Financial Services LLC | 112.0K | 0.44% | +7.0K | Jul 29, 2026 |
| UBS Group AG | 99.3K | 0.39% | −114.0K | Aug 13, 2026 |
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
Nothing filed in the last 12 months.
House and Senate disclosures
Not reported.